GOSSAMER BIO, INC. Shareholders' Equity
GOSSAMER BIO, INC. (GOSS) had Shareholders' Equity of -$94.03 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent -$94.03M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$161.48M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$122.76M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$82.33M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$94.03M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$161.48M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | -$122.76M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$82.33M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$46.11M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | -$6.25M 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $29.49M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $54.14M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $81.53M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $26.72M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $62.77M 10-K · filed 2026-03-17 | |
| 2023-09-30 | $104.62M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$62.80M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | -$28.46M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $12.08M 10-K · filed 2026-03-17 | |
| 2022-09-30 | $56.35M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$16.46M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $30.16M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $121.46M 10-K · filed 2025-03-13 | |
| 2021-09-30 | $169.81M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $220.69M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $272.08M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $320.68M 10-K · filed 2024-03-05 | |
| 2020-09-30 | $372.10M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $420.32M 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $306.46M 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $352.49M 10-K · filed 2023-03-17 | |
| 2019-09-30 | $398.87M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $441.44M 10-Q · filed 2020-11-10 | |
| 2019-03-31 | $480.26M 10-Q · filed 2020-11-10 | |
| 2018-12-31 | -$120.07M 10-K · filed 2022-03-03 | |
| 2018-09-30 | -$91.78M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$60.78M 10-Q · filed 2019-11-12 | |
| 2018-03-31 | -$29.42M 10-Q · filed 2019-11-12 | -$29.42M 10-Q · filed 2019-05-14 |
| 2017-12-31 | -$6.86M 10-K · filed 2021-02-26 | |
| 2016-12-31 | -$123.00K 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |